Entity
  • LiMM Therapeutics

    Created in 2018
  • BETA

    To investigate (B)
    Some signals may appear as inconsistent with a regular activity
  • Social networks

    95 2,838
  • Activities

  • Technologies

  • Entity types

  • Location

    198 Av. de France, 75013 Paris, France

    Paris

    France

  • Employees

    Scale: 2-10

    Estimated: 4

  • Engaged corporates

    0
    0 0
  • Added in Motherbase

    1 year, 3 months ago
Description
  • Value proposition

    LiMM is the biopharmaceutical company harnessing the molecular cross-talk between neuronal and innate lymphoid cells.

    LiMM is the biopharmaceutical company harnessing the molecular cross-talk between neuronal and innate lymphoid cells within peripheral tissues. By decoding the language of the neuroimmune cross-talk, we are developing first-in-class therapeutic products – NRILs: neuronal reprogrammers of innate lymphocytes - to preserve health and treat inflammatory, infectious and metabolic diseases. We are bridging neural sensing and immunology discoveries to unlock therapeutic solutions for the benefit of patients.

  • Limm Therapeutics

    DECODING THE LANGUAGE OF THE NEUROIMMUNE CROSS‑TALK: A new way to prevent and treat diseases through NRILs newly designed to reprogram the innate immune system

  • https://www.limmtx.com
  • Website is disabled or domain is for sale
Corporate interactions BETA
Corporate TypeTweets Articles
No interactions
Similar entities
Loading...
Loading...
Social network dynamics